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Dear friends and colleagues:
Ten years ago, IPM entered the microbicide field with a promise and a clear vision to create products that
women in developing countries could use to protect themselves against HIV. Every step we have taken since
has brought that vision into sharper focus. Today, we are as optimistic about our mission as we have ever been.
Building on recent successes in the HIV prevention field using antiretroviral drugs (ARVs) for prevention,
IPM has launched into late-stage efficacy trials a monthly vaginal ring designed to slowly release the ARV
dapivirine — bringing the product from concept to Phase III clinical trials in just seven years.
The AIDS epidemic continues to disproportionately affect women in developing countries, yet they lack practical tools they can use on their own, without the involvement of a male partner. IPM’s ring could help empower
women with a discreet and long-acting HIV prevention option that would allow them to take control of their
own health.
This 10th anniversary edition of our annual report reflects back on IPM’s history and looks ahead to the future.
As we lead the clinical studies needed for regulatory approval for the dapivirine ring with the Microbicide
Trials Network, we are also engaging in access planning, expanding our portfolio with multipurpose technologies and pursuing a pipeline of promising microbicide candidates, including combination ARV products.
This is not something IPM can achieve on its own. We extend our deepest thanks to our partners around the
world who amplify our efforts to improve women’s health, to our Board of Directors and scientific advisors for
their leadership, to the women who step forward to volunteer for HIV prevention studies, and to our donors,
whose foresight and generosity have helped support IPM’s progress.
Our work together has brought us from a promising concept to a potential new HIV prevention tool that could
help make a difference in the lives of millions. And together, we must renew our commitment to advancing
health solutions for the world’s women.

Dr. Zeda F. Rosenberg 						

Dr. Peter B. Corr
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A Decade of Progress
Since IPM was founded as a product development partnership (PDP) in 2002, we have leveraged public, philanthropic and
private sector resources to spur development of safe and effective life-saving technologies women can use to protect themselves against HIV. IPM builds on partnerships at every level — with governments, foundations, researchers, pharmaceutical
companies, policymakers, advocates and communities — to bring scientific ingenuity, political will and financial resources to
bear on all phases of microbicide development. This annual report highlights our 2011 accomplishments, and reviews IPM’s
decade of progress in HIV prevention as well as our plans for the future.

Planning for Access From the Start
In 2003, IPM began devising strategies for making a potential
microbicide available and accessible to women who need
it most. Since then, IPM has laid the groundwork for access
through licensing agreements, product acceptability and
market research studies, direct discussions with regulatory
agencies and country governments around the world, forums
hosted with the World Health Organization, relationships with
advocates, and product manufacturing strategies to keep
costs of future products affordable.

Plotting Scientific Direction and
Pipeline Expansion

Compound

License

Mechanism of action

Dapivirine

Janssen R&D Ireland/
Johnson & Johnson

NNRTI: stops virus from copying its genetic
material inside healthy cells

L167, L872, L882

Merck

CCR5 blocker: stops virus from entering
healthy cells

BMS 793

Bristol-Myers Squibb

gp120 binder: stops virus from entering
healthy cells

Tenofovir

Gilead

NRTI: stops virus from copying its genetic
material inside healthy cells

Maraviroc

ViiV Healthcare

CCR5 blocker: stops virus from entering
healthy cells

L’644 peptide

Merck

gp41 binder: stops virus from entering
healthy cells

IPM Negotiates First Royalty-Free ARV License
In 2004, IPM obtained its first non-exclusive, royalty-free ARV
license through a landmark public-private collaboration with
Janssen R&D Ireland, one of the Janssen pharmaceutical
companies of Johnson & Johnson. This agreement allowed
IPM to develop the ARV dapivirine as a microbicide — our first
step toward developing what is now IPM’s lead product, the
monthly dapivirine ring, and toward fulfilling our mandate to
expand the microbicide pipeline. Since 2004, IPM has negotiated five other royalty-free licenses from major pharmaceutical
companies that allow us to develop and manufacture a total
of eight different ARV compounds as microbicides for use in
developing countries. These licenses are essential to ensuring that IPM products will be affordable and accessible to the
populations who urgently need them.

2004

IPM and its Scientific Advisory Board (SAB) met for the first
time in 2003 to evaluate the current state of the microbicide
field and plot the scientific direction IPM would pursue to
advance a diverse pipeline of the most promising and viable
candidates. This early evaluation led to IPM’s focus on highly
potent antiretrovirals (ARVs) with multiple mechanisms of action, including reverse transcriptase and entry inhibitors. From
the start, IPM has focused exclusively on ARV compounds
given their success in treatment and ability to target HIV.
The SAB continues to review IPM’s progress in microbicide
product development, and to provide ongoing scientific advice
to staff and the Board of Directors.

IPM-licensed compounds

Building Research Capacity in Africa

IPM helped establish the Projet
Ubuzima site in Kigali, Rwanda.

With the license for dapivirine in hand, IPM began building
on Janssen’s earlier work to develop this potent ARV into
daily gels and long-acting vaginal rings. To prepare for future
clinical trials of these new products, we began in 2004 to build
research capacity in Africa. IPM worked with the AMC-CPCD
Foundation and other local groups to help establish Projet
Ubuzima, a new research center in Kigali, Rwanda, that has
participated in several IPM studies and will take part in our
Phase III efficacy trial for the dapivirine ring, pending in-country approvals. IPM has since helped launch nine more sites in
Africa, investing in infrastructure and staff training, and engaging governments, communities and individuals in our studies.
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Feasibility Results Are In — the Microbicide
Ring Moves Forward

“Ireland has been supporting IPM since the beginning of its journey in 2002. Ireland is a strong supporter of IPM’s work to help
end the AIDS epidemic by empowering women, who are disproportionately affected, to protect themselves from HIV infection. It
is a vital mission and one that will improve the lives of millions.”

IPM built a facility in the United States to expedite the
development and production of optimal vaginal microbicide
formulations for clinical safety trials. The first products designed and produced were multiple prototype dapivirine gels
for safety studies in 2005, which showed the gels to be safe
and well-tolerated. The facility addressed a bottleneck in the
speed and availability of manufacturing capacity, and helped
lower costs by shortening the time line to clinical trials.

Developing Products That Meet Women’s Needs
The promise of microbicides will be realized only if women use
them, so it is crucial that the needs and preferences of women
and their male partners inform product development from its
earliest stages. In 2006, IPM began its first acceptability study
of a microbicide gel in Africa to help identify the type of gel
women may prefer to use. In total, IPM has conducted three
product acceptability studies of different placebo microbicide
formulations (vaginal tablets, films, capsules, gels and rings)
among more than 1,200 women in five countries in Africa.
These studies have shown that vaginal products are acceptable to women, with preferences varying by country — a finding
that suggests developing a variety of product options is vital, as
has also been observed in the contraceptive field. In particular,
IPM’s ring has shown very high acceptability among women
and their male partners.

— Barbara Cullinane, Head of Thematic Sectors and Special Programmes
Section, Irish Aid

Prioritizing Products:
Why Dapivirine Ring?
IPM engages in a rigorous prioritization process to identify
products that show the most promise in achieving IPM’s
mission to develop safe and effective HIV prevention tools
women will use. IPM prioritized dapivirine for development
from among other drugs of the same class on the basis of
multiple factors, including supportive preclinical and clinical data, and access considerations. The ring as a delivery
device complements the attributes of dapivirine due to its
stability, acceptability, ease-of-use, long-acting duration,
and potential to deliver more than one ARV as well as an
ARV along with a contraceptive hormone. Given its ability
to be used for a month or potentially longer, the ring could
help ensure consistent use and, therefore, effectiveness.
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The year 2005 marked the completion of IPM’s first study of
the early dapivirine ring prototype to assess feasibility and
safety, which was conducted in partnership with Janssen
R&D Ireland and the Population Council. Results showed that
the ring released dapivirine efficiently, and was safe and welltolerated among healthy, HIV-negative women. The product
was the first to adapt a medical technology commonly used to
deliver hormones to women — the vaginal ring — to the fight
against HIV. This study set the stage for improvements in the
ring’s design and its application to other drugs in IPM’s pipeline. Future collaborations on the ring’s development included
Queen’s University Belfast and Warner Chilcott. To date, IPM
has led a total of 14 clinical trials of dapivirine in both gels
and rings across Africa, Europe and the United States, from
Phase I studies to expanded Phase I/II safety studies in Africa
as well as our current Phase III efficacy study of dapivirine
ring, known as The Ring Study.

IPM Launches Manufacturing Facility

2007

Scaling Up for Larger Studies
Focused capacity-building efforts at five of IPM’s research
center partners in 2007 helped lay the complex groundwork
for expanded safety studies of the dapivirine ring and gel in
Africa in 2009-10, and the Phase III program now underway. In
collaboration with developing country partners, these efforts included renovating clinic space, updating medical and telecommunications equipment, hiring and training staff, and developing community engagement strategies. In addition to helping
establish 10 research centers in Africa, IPM has collaborated
with more than 20 centers in all, benefitting from their expertise
conducting clinical trials in developing country settings and
partnering to advance the science of HIV prevention.
Long-term benefits of capacity-building: IPM’s studies are
also benefitting the areas hardest hit by the HIV epidemic —
by strengthening community understanding of HIV, expanding
HIV testing and counseling, improving research capacity and
access to health services, providing hundreds of employment
and professional development opportunities, and supporting
the development of frameworks such as community advisory
boards. These research centers continue to serve their communities after trials end by conducting studies with other trial
sponsors, expanding their research portfolios and supporting
community health needs.

IPM has conducted product
acceptability, HIV incidence and
clinical research studies in more
than 10 countries to date.

“Initiatives such as IPM’s new Ring Study, which allows
women to actively participate in prevention of HIV infection,
must be supported and emulated to ensure a measurable
decrease in the spread of HIV/AIDS in our communities
and regions.”
— Graça Machel, global advocate for women’s and children’s rights

IPM Expands Manufacturing Facility to Speed
Ring Development

2008

The MatCH research center in
Edendale, South Africa, was
established in 2007 with support
from IPM. We also completed
renovations that year to three
other research centers in South
Africa: Madibeng Centre for
Research, the Prevention of HIV/
AIDS Project, and the Qhakaza
Mbokodo research center. All
four centers have conducted IPM
research studies and are now
participating in our Phase III
Ring Study.

To design a stable and affordable vaginal ring that could
provide sustained release of dapivirine, IPM expanded its
manufacturing facility in 2008 to develop microbicide rings.
IPM manufactured both dapivirine rings and placebo rings
to supply Phase I/II safety trials over the next two years as
we worked in parallel to establish a scalable manufacturing
process — overcoming a significant technical hurdle to speed
the ring’s development. Starting in 2010, IPM transferred this
process to QPharma in Malmö, Sweden, where rings are
produced at a larger scale to supply IPM’s Phase III clinical
program. Through our in-house ring development and manufacturing efforts, IPM gained valuable technical expertise that
continues to play a critical role in the program today as we
work toward product licensure.
Which photo?
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Galvanizing Support Through Advocacy
In 2008, IPM contributed to advocacy efforts at the G8
International Parliamentarians’ Conference that led to a call
for all G8 countries to increase investment in new disease
prevention technology development such as microbicides.
The G8 statement is one of more than 10 multilateral global
development commitments and policies that include support
for microbicide research as a result of efforts by IPM and
our partners. Since our inception, IPM has helped develop a
network of civil society partners across Europe, sub-Saharan
Africa and North America to galvanize political will, public
support and financial commitment for microbicide R&D and
future product access.

Sharing Scientific Progress

IPM presenting at an International
AIDS Conference.
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Between 2009 and 2010, IPM began expanded Phase I/II safety trials of dapivirine gel and ring, based on supportive data
from earlier safety studies. During this time, we implemented
a total of six studies evaluating the safety, acceptability and
pharmacokinetic profile of the products. These studies took
place in five African countries, Belgium and the United States.
The gel studies piloted an innovative design called “daily
monitored adherence” or DMA, during which study participants had daily contact with researchers either by home visits
or local drop-off centers where they returned the daily-use gel
applicators. Results from these studies showed dapivirine, in
both gel and ring form, was safe and well-tolerated in healthy,
HIV-negative women, and supported the dapivirine ring’s
advancement to Phase III efficacy studies.

HIV Incidence Studies Point The Way to Phase III
Determining incidence — or the rate of new infections — in
communities most profoundly affected by HIV helps to supply
researchers and national governments with needed data on
the size and scope of the epidemic in local communities so
they can effectively target prevention efforts. These studies also help determine possible locations for future HIV
prevention trials to ensure the trials demonstrate meaningful
results as quickly as possible. For example, a 2010 IPM study
at five sites in South Africa confirmed annual HIV incidence
rates ranging between 4 percent and as high as 11 percent.
IPM research center partners in the
KwaZulu-Natal province of South Africa are
participating in IPM’s Phase III study of the
dapivirine ring. In all, IPM has conducted
a total of 13 incidence studies since 2004,
involving thousands of women across subSaharan Africa.

2010

IPM has added to the body of scientific contributions in
microbicide research through publishing peer-reviewed
journal articles and presenting data at major international
conferences, including the Conference on Retroviruses
and Opportunistic Infections, the International AIDS
Conference and the South African AIDS Conference. For
example, in 2010 alone, IPM led or supported work that
was featured in more than
20 oral presentations and
17 posters at the International Microbicides 2010
Conference.

Ushering in Progress
With Expanded Safety Studies

2009

In 2011, IPM coordinated a field-wide
advocacy effort to brand microbicides
across Africa as a potential new HIV
prevention product.

2005-6:

Male circumcision found to reduce risk of HIV
infection in men by more than half

2009:

RV-144 study shows for the first time that the risk
of HIV infection can be reduced by a vaccine

2010:

First proof-of-concept established for ARVbased prevention: tenofovir microbicide gel for
women, and Truvada as pre-exposure prophylaxis (PrEP) for men who have sex with men

2011:

Daily PrEP is found to reduce HIV infection
among discordant heterosexual couples and
adults by up to 73%

2011:

Early initiation of ARV therapy by HIV+ individuals protects uninfected partners by 96%

Joined Against a Global Foe
IPM and the US National Institutes of Health-funded Microbicide Trials Network (MTN) joined forces in 2011 to implement
Phase III trials of the dapivirine ring. This partnership follows
a formal agreement forged in 2005 by IPM and the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH,
to accelerate microbicide development, opening the door to
scientific cooperation and information-sharing. IPM and MTN
also jointly brought the first combination ARV microbicide, the
dapivirine-maraviroc ring, into Phase I clinical safety trials in
2011. This is the first study to evaluate the ARV maraviroc (an
entry inhibitor) as a
microbicide (see
chart p. 1). In addition,
IPM and MTN collaborated on a male
tolerance study of
dapivirine gel.

The year 2011 saw the culmination of
IPM’s clinical and community engagement efforts as we prepared to launch
our lead product, the dapivirine ring,
into Phase III clinical trials. In the
seven years since we negotiated a
royalty-free license with Janssen, IPM
conducted preclinical work on dapivirine, developed and optimized several
ring designs, manufactured the product
for Phase I and Phase I/II clinical trials,
conducted six clinical safety trials of the dapivirine ring
alongside 25 other research studies through 2011, and
launched the Phase III efficacy program for the ring,
now underway. As a platform technology, the ring is also
being used to design a multipurpose prevention product
that combines an ARV with a contraceptive as well as a
combination product that could deliver multiple ARVs.

		
		
		

IPM Launches its Licensure 		
Program With First Efficacy Trial
of a Microbicide Ring

2012

2011

Landmark studies in the field since 2005 have shown the
great progress made in HIV prevention, especially
with ARV-based strategies.

From Promise to Phase III in 7 years

2011

Milestones
in the HIV prevention field

In 2012, IPM launched The Ring Study — the first efficacy
and long-term safety study of a microbicide ring for HIV
prevention, with results expected in 2015. The study will
be conducted among 1,650 women in South Africa, and
pending in-country approvals, Rwanda. IPM’s ring slowly
releases the ARV dapivirine over the course of a month to
provide discreet and easy-to-use protection against HIV.
Regular use of prevention tools is essential to their effectiveness, and because IPM’s ring would be used monthly,
it may help encourage women to use it consistently. The
Ring Study is part of a broader licensure program being
conducted in partnership with the MTN, which also
includes MTN’s larger Phase III ASPIRE study, to launch
in 2012. Together, these sister studies, along with other
smaller supporting safety studies, are designed to provide
the strength of evidence needed for product licensure for
the dapivirine ring.

A DECADE OF PROGRESS
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What does the future hold?
Access: Getting Ready Together
If results from the studies in IPM’s dapivirine ring licensure
program show the ring to be effective and safe for long-term
use, we will seek regulatory approval for product licensure,
and collaborate with key partners to help ensure it is made
available at low cost to women in developing countries as
soon as possible. IPM and its network will continue to refine
our access strategy throughout the ring licensure program to
expedite the product’s roll-out, availability and affordability,
including potential distribution and financing mechanisms. We
are also working to optimize manufacturing processes and
scale-up to minimize the cost of production. In addition, IPM
is evaluating whether the ring could be used for 60 days or
longer to provide additional cost savings in the future.

Multipurpose Prevention Technologies:
Advancing Solutions That Meet Multiple
Health Needs
High rates of HIV and unintended pregnancy are significant causes of health complications and death for young
women worldwide – demonstrating a clear need for discreet,
long-acting tools women can use to address these issues
in tandem. Through a grant from USAID, IPM is developing
a 60-day dual-purpose ring, currently in preclinical stages,
that combines the ARV dapivirine with a contraceptive to
address women’s urgent HIV prevention and reproductive
health needs in a single product. The dual-purpose dapivirinecontraceptive ring could empower women with a convenient
and easy-to-use way to protect their health.

“Bravo to team IPM for their decade of commitment developing
tools to empower women with HIV prevention. IPM’s pioneering
work on microbicides has been impressive to watch, and we were
thrilled to see its expansion into family planning with research on
a multipurpose ring to prevent HIV and pregnancy. Women Deliver
is excited to see what the next decade brings with IPM’s efforts to
protect the health of women and girls around the world.”
— Jill Sheffield, President, Women Deliver

Advancing a Diverse Product Pipeline
As IPM oversees the dapivirine ring licensure program, prepares for access, and expands its portfolio with multipurpose
prevention technologies, we are also developing a pipeline of
other candidates in a variety of novel formulations to expand
women’s options and move the science of HIV prevention
forward. IPM is working on multiple active ARV drugs with
different mechanisms of action, including a gp120 binder and
entry inhibitors such as maraviroc. IPM is formulating these
compounds as gels, rings, films and tablets, both as singleagents and combination products. Combination ARV
products would target HIV at different points in its life
cycle and may provide greater protection against
HIV than a single drug alone.

IPM Donors since 2002
Ackerman Family Foundation
Belgian Development Cooperation
Bill & Melinda Gates Foundation
Canadian International Development Agency
European Commission
Federal Ministry for Economic Cooperation and Development, 		
Germany
Irish Aid, Department of Foreign Affairs     
M•A•C AIDS Fund
Magee-Womens Research Institute and Foundation
Ministry for Foreign Affairs, Sweden
Ministry of Foreign Affairs and Cooperation, Spain

Ministry of Foreign Affairs, France
Ministry of Foreign Affairs of Denmark
Ministry of Foreign Affairs, the Netherlands
Norwegian Ministry of Foreign Affairs
OPEC Fund for International Development
Rockefeller Foundation
Swedish International Development Agency
United Kingdom Department for International Development
United Nations Population Fund
United States Agency for International Development
World Bank
With special thanks to Unit4 Business Software
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Zeda F. Rosenberg, ScD
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International Community of Women Living with
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United States
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Funding Considerations
IPM’s cash available balance entering 2012 was $43 million.
In a climate of continued global recession and the resulting
financial impact, IPM streamlined costs by refining our work
model and cost structure, and by prudently managing the
product pipeline. IPM contained costs, made staffing adjustments and enhanced existing financial and operational systems to support management decision-making and program
implementation.
Consistent with our ongoing efforts to match expenses with
budget realities, 2011 was a year of fiscal and operational
preparation for implementation of the dapivirine ring licensure program in 2012. Conducting clinical trials in developing
countries requires substantial investments to improve infrastructure and train research center staff to support thousands

Assets

Dec. 31, 2011

Cash and cash equivalents
Investments
Accounts receivables
Prepaid expenses and other assets
Property and equipment, net
Total Assets

$11,717,269
$34,124,359
$1,998,497
$1,188,891
$4,603,968
$53,632,984

Liabilities and Net Assets
Liabilities
Accounts payable and accrued expenses
Grants advances and deferred revenue
Total liabilities

$3,138,877
$28,615,297
$31,754,174

of trial participants over several years. Investment is also
required to maintain the program and operations support
needed for product evaluation. To comply with the requirements of in-country institutional review boards, IPM worked
to ensure all necessary funds for the Phase III dapivirine ring
trial were in place in 2011.
As IPM oversees the dapivirine ring licensure program, we
will also reemphasize pipeline and continue preparing for
access, given the potential for the dapivirine ring to be proven
safe and effective. With new partnerships, an experienced
management team and a committed Board of Directors, IPM
is well-positioned to advance its mission of developing HIV
prevention tools for women in developing countries.

Expenses by Department
Resource
Development
3%

Regulatory
5%

External
Relations
9%

Total liabilities and net assets

Operations
21%

Clinical Programs
26%

Net Assets
Unrestricted
Temporarily restricted
Total net assets

Quality Assurance
3%

Product Development
33%

$21,878,810
$0
$21,878,810

$53,632,984

To learn more about how to prevent HIV in women worldwide and help save millions of lives, visit www.IPMglobal.org.
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